BridgeBio (BBIO) CEO trusts disclose Rule 10b5-1 stock sales in filing

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. insider activity centers on trusts associated with its Chief Executive Officer. A Form 4 reports that on January 8 and 9, 2026, the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, for which the CEO is a co‑trustee, sold multiple blocks of BridgeBio common stock under a Rule 10b5‑1 sales plan adopted on March 31, 2025.

The reported weighted average sale prices for these transactions range from about $73.05 to $78.32 per share, with examples including 11,515 shares at a weighted average price of $73.6446 and 10,519 shares at $77.6086. Following the reported trades, the family irrevocable trust held 715,686 shares, the revocable trust held 4,518,447 shares, and 228,776 shares were held directly. The reporting person disclaims beneficial ownership of the trust‑held shares except to the extent of any pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		S(1)		11,515	D	$73.6446(2)	744,171	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/08/2026		S(1)		8,085	D	$74.3773(4)	736,086	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/08/2026		S(1)		400	D	$75.1602(5)	735,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/08/2026		S(1)		11,565	D	$73.6542(6)	4,546,882	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/08/2026		S(1)		8,135	D	$74.3775(7)	4,538,747	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/08/2026		S(1)		300	D	$75.2033(5)	4,538,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/09/2026		S(1)		2,151	D	$75.752(8)	733,535	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/09/2026		S(1)		6,955	D	$76.7173(9)	726,580	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/09/2026		S(1)		10,519	D	$77.6086(10)	716,061	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/09/2026		S(1)		375	D	$78.192(11)	715,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/09/2026		S(1)		1,401	D	$75.6088(12)	4,537,046	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/09/2026		S(1)		6,067	D	$76.527(13)	4,530,979	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/09/2026		S(1)		10,677	D	$77.4577(14)	4,520,302	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	01/09/2026		S(1)		1,855	D	$78.1035(15)	4,518,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock								228,776	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

2. Represents the weighted average sale price of the shares sold from $73.05 to $74.03 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

4. Represents the weighted average sale price of the shares sold from $74.06 to $74.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. Represents the weighted average sale price of the shares sold from $75.09 to $75.28 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

6. Represents the weighted average sale price of the shares sold from $73.08 to $74.06 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

7. Represents the weighted average sale price of the shares sold from $74.08 to $75.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

8. Represents the weighted average sale price of the shares sold from $75.12 to $76.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

9. Represents the weighted average sale price of the shares sold from $76.13 to $77.125 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

10. Represents the weighted average sale price of the shares sold from $77.16 to $78.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

11. Represents the weighted average sale price of the shares sold from $78.16 to $78.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

12. Represents the weighted average sale price of the shares sold from $74.99 to $75.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

13. Represents the weighted average sale price of the shares sold from $75.99 to $76.985 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

14. Represents the weighted average sale price of the shares sold from $76.99 to $77.96 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

15. Represents the weighted average sale price of the shares sold from $78.00 to $78.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the reporting person in the BridgeBio (BBIO) Form 4 filing?

The reporting person is Kumar Neil, who serves as a Director and Chief Executive Officer of BridgeBio Pharma, Inc. as indicated in the Form 4.

What kind of transactions were reported in this BridgeBio (BBIO) Form 4?

The filing reports sales of common stock (transaction code S) on January 8 and 9, 2026 by trusts associated with the CEO, at various weighted average prices in the $73–$78 per share range.

Which entities actually sold BridgeBio common stock in this Form 4?

Shares were sold indirectly through the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, each described as being co‑trusteeed by the reporting person.

Were the BridgeBio (BBIO) stock sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states that the transactions were effected pursuant to a Rule 10b5‑1 sales plan adopted by the reporting person on March 31, 2025.

What were the holdings after the reported BridgeBio stock sales?

After the transactions, the Form 4 shows the Kumar Haldea Family Irrevocable Trust holding 715,686 shares, the Kumar Haldea Revocable Trust holding 4,518,447 shares, and 228,776 shares held directly.

Does the CEO claim full beneficial ownership of the trust-held BridgeBio shares?

No. A footnote states that the reporting person disclaims beneficial ownership of the trust‑held shares except to the extent of any pecuniary interest therein, if any.

How are the reported BridgeBio sale prices presented in the Form 4?

For each sale line, the Form 4 gives a weighted average sale price and explains in footnotes that the underlying trades occurred within specified price ranges, such as $73.05 to $74.03 or $78.00 to $78.32 per share.